Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Key Insights & Takeaways: 1 A Paradigm Shift Meets Prescriber Inertia: Despite being a first-in-class mechanismapproved in 2024 as the only novel schizophrenia therapy in decadesCOBENFY (xanomeline and trospium chloride) US HCP faces deeply ingrained D2 prescribing habits, as noted by BMS leadership
Note: Figures and projections outlined in this report are the result of Polaris Market Researchs proprietary analytical processes, grounded in the latest available datasets and market observations
This was based on the SURMOUNT-OSA trial data
Mounjaro versus Zepbound: the billing difference explained Same molecule
Any additional requests for information can be directed to, and will be fulfilled by, the corresponding authors
Theyre also used in medications to treat conditions such as endocrine disorders, multiple sclerosis, and infantile spasms (or a form of epilepsy) in children under two years of age, as well as to control the level of calcium in the blood
